In a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the biotech industry, where a single clinical trial outcome can send...
Argenx is another biotech stock setting up in a textbook breakout pattern. Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market. ARGX still held up well, and will likely continue its advance higher.
Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0% Funds Holding: 185 170 8.82% 63 (3.7%) 55 (3.19%) 14.55% 13F shares: 28.505...
if this thing can keep trending up and break 90 I may just have to take it out for a spin, to make gains and purely only for gains. Bullish baby please on a nightly and daily basis.